[Therapeutic management of hypercholesterolemia].
FUNDAMENTAL PRINCIPLES: Therapeutic management of hypercholesterolemia requires information on two fundamental aspects: the patient's lipid profile and his/her risk of coronary artery disease.
The latest therapeutic trials have partially confirmed the LDL-cholesterol levels retained for the different guidelines, including those proposed by the ANDEM. It is clear however, that the assessment of the individual beneficial effect of primary prevention must be based on a multifactorial evaluation of risk. But there is no standardization of methodologies currently used to evaluate risk. Briefly, these methodologies use mathematical equations deducted from statistical models or noninvasive quantification of preclinical atherosclerosis.


CONCLUSIONS
In the future, this strategy based on quantification of cardiovascular risk should be evaluated in a prospective study.
Mégnien
J L
JL
Centre de Médecine Préventive Cardiovasculaire, Hôpital Broussais, Paris. Jean-louis.megnien@brs.ap-hop-paris.fr
Simon
A
A
D000924:Anticholesteremic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications / Q000175:diagnosis; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D005544:Forecasting; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D012537:Scandinavian and Nordic Countries; D012606:Scotland; D019821:Simvastatin / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019821:Simvastatin